Home
 /
Papers
 /
Immunology
 /
Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening
Preprint
Open access
Top 1% · Validated by QED

Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening

Ting Pan, Tingting Wang, Jiaqi Wu +15 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.01.19.699861
99
%
QED Score
QED Impressions

By establishing myeloid CD209 as a mechanical immune checkpoint that physically stiffens T cells via ICAM-2–ROCK1–ERM signaling, this work overturns the biochemical-only checkpoint paradigm and opens immunotherapy access to refractory cold tumors.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

CD209, a C-type lectin receptor expressed on tumor-infiltrating M2 macrophages and monocytes, functions as a myeloid-derived mechanical immune checkpoint that suppresses antitumor T-cell immunity by binding ICAM-2 on T cells to trigger ROCK1-ERM-mediated cortical stiffening, thereby destabilizing T-cell-APC conjugation and attenuating TCR signaling; therapeutic blockade of CD209 with neutralizing antibodies overcomes this suppression to achieve robust tumor regression across multiple models including immunotherapy-refractory cold tumors such as ovarian cancer and glioblastoma, while elevated CD209 expression in human cancers inversely correlates with CD8+ T-cell infiltration and predicts resistance to PD-1 blockade therapy.

See full analysis
Main Claim 1 –

CD209 Upregulated in Tumor M2 Macrophages and Monocytes

Supporting evidence

  • High CD209 Predicts Immunotherapy Resistance and Elevated TIDE Scores
  • CD209+ Myeloids Correlate with CD8 Exclusion and Poor Survival
Main Claim 2 –

CD209 Binds T Cells and Inhibits TCR Activation

Supporting evidence

  • Neutralizing Anti-CD209 Antibodies Reverse CD209 T-Cell Suppression
Main Claim 3 –

CD209 Blockade Boosts T-Cell Immunity and Regresses Cold Tumors

Supporting evidence

  • CD209 Blockade Expands CD8 Effector T Cells and Reduces M2
  • CD209 Blockade Requires CD8 T Cells and Tumor Myeloids
  • CD209 Blockade Selectively Depletes PMN-MDSCs in Tumors
  • Humanized Anti-CD209 IgG4 Retains Fc-Independent Antitumor Efficacy
  • CD209 Blockade Works in Human Tumors Ex Vivo and Humanized Mice
  • Focused Ultrasound Enables Anti-CD209 Delivery Across the Blood-Brain Barrier
Main Claim 4 –

ICAM-2 Is Required for CD209-Mediated T-Cell Suppression

Supporting evidence

  • ICAM-2 Is Higher on CD8 than CD4 T Cells

Abstract

Cancer immunotherapy has achieved durable clinical benefit in a subset of patients; however, most solid tumors—particularly immunologically “cold” tumors—remain refractory due to profound T-cell exclusion and dysfunction within the tumor microenvironment (TME). Here, we identify CD209 (DC-SIGN), a C-type lectin receptor expressed by tumor-infiltrating myeloid cells, as a previously unrecognized myeloid-derived mechanical immune checkpoint that suppresses antitumor T-cell immunity. Using human CD209 knock-in mice, we demonstrate that therapeutic blockade of CD209 markedly enhances T-cell infiltration and activation, resulting in robust tumor regression across multiple models, including ovarian cancer and glioblastoma. Mechanistically, CD209 directly engages intercellular adhesion molecule 2 (ICAM-2) on T cells, triggering ezrin/radixin/moesin (ERM) phosphorylation and increasing T-cell cortical stiffness. This biophysical reprogramming destabilizes T cell–antigen-presenting cell conjugation and attenuates T-cell receptor signaling. Analyses of human cancer datasets and primary tumor specimens reveal that elevated CD209 expression inversely correlates with CD8⁺ T-cell infiltration and is associated with reduced overall survival. Moreover, CD209 expression is significantly enriched in PD-1 therapy non-responders and positively correlates with TIDE (Tumor Immune Dysfunction and Exclusion) scores across multiple cancer types. Together, these findings establish CD209 as a central regulator of myeloid-driven T-cell mechanical dysfunction and highlight its potential as a therapeutic target and a candidate companion diagnostic biomarker for immunotherapy response.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?